The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The targeted therapy has increased the ten-year survival rate of patients from around 20% to 80–90% [157].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [157]
In the citing paper
“A significant shift in CML treatment occurred during the early 1990s following the identification of Imatinib mesylate (IM), which became the primary therapy for patients because of its targeted inhibition of Bcr-Abl protein tyrosine kinase activity.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Flagged first, then by citations
Research works printed but not linked: 27
- Kolibaba, 1997, Biochim Biophys Acta, 1333, F217
- Heisterkamp, 1983, Nature, 306, 239, 10.1038/306239a0 · DOI
- Bartram, 1983, Nature, 306, 277, 10.1038/306277a0 · DOI
- Shtivelman, 1985, Nature, 315, 550, 10.1038/315550a0 · DOI
- Ben-Neriah, 1986, Science, 233, 212, 10.1126/science.3460176 · DOI
- Konopka, 1984, Cell, 37, 1035, 10.1016/0092-8674(84)90438-0 · DOI
- Kurzrock, 1988, N Engl J Med, 319, 990, 10.1056/NEJM198810133191506 · DOI
- Hermans, 1987, Cell, 51, 33, 10.1016/0092-8674(87)90007-9 · DOI
- Clark, 1988, Science, 239, 775, 10.1126/science.3422516 · DOI
- Rosenberg, 1988, Adv Virus Res, 35, 39, 10.1016/S0065-3527(08)60708-3 · DOI
- Daley, 1990, Science, 247, 824, 10.1126/science.2406902 · DOI
- Kelliher, 1990, Proc Natl Acad Sci USA, 87, 6649, 10.1073/pnas.87.17.6649 · DOI
- Lugo, 1990, Science, 247, 1079, 10.1126/science.2408149 · DOI
- Buchdunger, 1995, Proc Natl Acad Sci USA, 92, 2558, 10.1073/pnas.92.7.2558 · DOI
- Buchdunger, 1996, Cancer Res, 56, 100
- Zimmermann, 1996, Arch Pharm (Weinheim), 329, 371, 10.1002/ardp.19963290707 · DOI
- Druker, 1996, Nat Med, 2, 561, 10.1038/nm0596-561 · DOI
- Carroll, 1997, Blood, 90, 4947, 10.1182/blood.V90.12.4947 · DOI
- Deininger, 1997, Blood, 90, 3691, 10.1182/blood.V90.9.3691 · DOI
- le Coutre, 1999, J Natl Cancer Inst, 91, 163, 10.1093/jnci/91.2.163 · DOI
- Beran, 1998, Clin Cancer Res, 4, 1661
- Druker, 1999, Blood, 94, 368a, 10.1182/blood.V94.1.368.413a47_368_371 · DOI
- Oda, 1994, J Biol Chem, 269, 22925, 10.1016/S0021-9258(17)31596-X · DOI
- Toledo, 1999, Curr Med Chem, 6, 775, 10.2174/092986730609220401150028 · DOI
- Traxler, 1997, J Med Chem, 40, 3601, 10.1021/jm970124v · DOI
- Zhu, 1999, Structure Fold Des, 7, 651, 10.1016/S0969-2126(99)80086-0 · DOI
- Schindler, 1999, Mol Cell, 3, 639, 10.1016/S1097-2765(00)80357-3 · DOI
Cited by
Sorted by citations
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
The role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Metadata
- Authors
- Druker, B. J., & Lydon, N. B.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-01-01
- Volume
- 105
- Issue
- 1
- Pages
- 3-7
- ISSN
- 0021-9738
- Cited by
- 707
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
